Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Receivables (2016 - 2025)

Perspective Therapeutics' Receivables history spans 15 years, with the latest figure at $179000.0 for Q3 2025.

  • For Q3 2025, Receivables fell 17.51% year-over-year to $179000.0; the TTM value through Sep 2025 reached $179000.0, down 17.51%, while the annual FY2024 figure was $603000.0, 48.68% down from the prior year.
  • Receivables for Q3 2025 was $179000.0 at Perspective Therapeutics, down from $225000.0 in the prior quarter.
  • Across five years, Receivables topped out at $2.1 million in Q1 2022 and bottomed at $78000.0 in Q1 2025.
  • The 5-year median for Receivables is $1.2 million (2022), against an average of $1.1 million.
  • The largest YoY upside for Receivables was 58.45% in 2025 against a maximum downside of 92.19% in 2025.
  • A 5-year view of Receivables shows it stood at $1.6 million in 2021, then dropped by 17.12% to $1.4 million in 2022, then decreased by 13.92% to $1.2 million in 2023, then tumbled by 48.68% to $603000.0 in 2024, then tumbled by 70.32% to $179000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Receivables are $179000.0 (Q3 2025), $225000.0 (Q2 2025), and $78000.0 (Q1 2025).